<DOC>
	<DOCNO>NCT01358929</DOCNO>
	<brief_summary>This randomize , placebo-controlled , multiple ascend dose study evaluate safety , tolerability , pharmacokinetics pharmacodynamics RO6807952 . Patients receive multiple weekly subcutaneous dos RO6870952 . The anticipated time study treatment 8 week .</brief_summary>
	<brief_title>A Study RO6807952 Patients With Diabetes Mellitus Type 2</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Adult patient , 18 70 year age , inclusive Diagnosis type 2 diabetes &gt; /=3 month &lt; /=10 year prior screen Fasting plasma glucose &gt; /=110 mg/dL &lt; /=240 mg/dL Patients stable dose metformin least 2 month prior screen Hemoglobin HbA1c &gt; /=6.5 % &lt; /=10.5 % Body mass index &gt; /=25 kg/m2 &lt; /=42 kg/m2 Systolic blood pressure &lt; 155 mmHg diastolic blood pressure &lt; 95 mmHg Patients type 1 diabetes History significant renal hepatic disease History metabolic acidosis diabetic gastroparesis History pancreatitis History coagulation disorder unexplained excessive bleeding History clinically significant cardiovascular disease severe symptomatic hypoglycemia within 6 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>